Scholar Rock Wins FDA Approval — and the Stock Sold Off Anyway

Scholar Rock won FDA approval on Friday, September 11, for its first muscle-targeted spinal muscular atrophy treatment — and by the close on Monday, the stock had fallen 6.4%. It rose 9 percent in pre-market Monday trading, then sold off through the session to close at $51.85.

Approval is supposed to be the part where the market says "finally." The sell-off after initial enthusiasm tells you something the headline does not: investors are looking past the regulatory win and weighing what Scholar Rock can actually deliver as a business, not a research program.

That distinction matters. The company now has a market cap of $6.3 billion. It also has zero revenue, burned $297 million in free cash flow over the trailing twelve months, and has spent every quarter of 2025 and 2026 losing well over $100 million. The approval removes the biggest binary risk. It does not answer whether the economics can justify the price.

The drug works. The question is how many patients and at what price.

ISEMBYLD (apitegromab) is approved for adults and children ages 2 and older with SMA who are already on an existing SMN2-targeted treatment. It is not a standalone therapy — it is an add-on. It works by blocking myostatin, a protein that limits muscle growth, directly targeting the muscle weakness that existing treatments do not address. In the pivotal SAPPHIRE trial of 188 patients, those on ISEMBYLD showed a 2.2-point improvement in motor function scores compared to placebo, while the placebo group lost motor function over the same year.

The mechanism is real. The clinical data cleared the bar. But the approval came with a fracture risk warning — 9 percent of patients on the recommended dose suffered fractures versus 2 percent on placebo — and the treatment requires intravenous infusions every four weeks. This is not a set-it-and-forget-it pill.

The list price is $11,659 per single-use vial. The company has told investors the net annual cost for a typical patient runs approximately $310,000, varying with patient weight. Leerink Partners analysts project peak annual sales of around $2 billion.

That peak sales figure deserves scrutiny. SMA affects an estimated 10,000 to 25,000 patients in the United States. The approval covers only those ages 2 and older who are already on existing therapy — not the full population. At $310,000 per patient per year, it would take roughly 6,500 patients to hit $2 billion in sales. That is not unreasonable for a rare-disease drug with broad approval, but it assumes rapid adoption, wide insurance coverage, and minimal competitive erosion. None of these are guaranteed.

The company has to fund its way there.

Scholar Rock lost $378 million in 2025 and $105 million in the first quarter of 2026. Revenue was $0 in every reported quarter. The company had $437 million in cash as of the latest data, with total debt of $270 million and a $550 million credit facility available from Blue Owl Capital, with tranches tied to milestones including FDA approval. That debt cushion is real — the approval unlocks up to $150 million of additional borrowing capacity — but it is not equity. It does not strengthen the balance sheet; it just delays the question of when revenue must replace borrowing.

The company spent $208 million on research and development in 2025 and $176 million on general and administrative expenses. G&A more than doubled from $67.5 million in 2024 to $176.2 million in 2025, largely to build out the commercial launch infrastructure. That investment has to be repaid by drug sales that have not yet started.

Scholar Rock received a rare pediatric disease priority review voucher with the approval. These vouchers can be sold for nine-figure sums. Scholar Rock has not said whether it will sell, but at any price, a voucher sale is a one-time cash infusion, not a repeatable business.

The SMA market is crowded, and no one owns it.

The global SMA treatment market is estimated at $5.9 billion in 2025 and projected to reach $8.9 billion by 2032. Three major drugs already serve this space. Roche's Evrysdi is the market leader among ongoing therapies. Biogen's Spinraza, approved in 2016, still holds a foothold. Novartis's Zolgensma — the one-time gene therapy that once commanded $2.1 million per dose and peaked at $1.37 billion in annual sales — has been declining, falling 17 percent year over year in the second quarter of 2025, as newborn screening shifted diagnosis earlier and the addressable pool shrank.

ISEMBYLD enters this market not as a disruptor but as an add-on to the existing standard of care. Patients already on Spinraza, Evrysdi, or Zolgensma may now add ISEMBYLD to their regimen. That means Scholar Rock is not replacing these competitors; it is sharing the bill with them. It also means every one of those companies has an incentive to defend their position. Roche just got FDA approval for an oral tablet version of Evrysdi. Novartis secured approval in November 2025 to expand Zolgensma to patients ages 2 and older — the same population ISEMBYLD targets.

This is not a winner-take-all market. It is a crowded field where Scholar Rock's drug is the newest entrant and the one with the smallest commercial infrastructure.

What $6.3 billion is asking you to believe

A $6.3 billion market cap for a company with no revenue is a vote of confidence in future cash flows. The question is whether the path from $0 to the revenue level that justifies this valuation is narrow enough to warrant caution.

The math requires ISEMBYLD to capture a meaningful share of the SMA market quickly, at a price that payers accept, without the company running out of cash or diluting shareholders in the interim. The $2 billion peak sales estimate, if it materializes, would support that valuation. But getting there means three to five years of heavy spending, competitive pressure, and reimbursement battles — all before the company proves it can actually sell at scale.

The stock's reaction — initial pop, then sell-off — suggests professional money sees the approval as important but not sufficient. The approval removes the risk of a "no." It does not remove the risk of a "not enough."

For a retail investor, the question is not whether ISEMBYLD works. The clinical data answers that. The question is whether Scholar Rock can transition from a cash-burning research company into a profitable business fast enough to validate the current price. The approval makes that transition possible. It does not make it certain. The $297 million annual burn rate and $6.3 billion valuation are in tension — and the resolution of that tension will take years of revenue reports, not one FDA letter.